Alcoholic Hepatitis
Alcoholic Hepatitis is a serious liver condition caused by excessive alcohol consumption, leading to inflammation and damage to the liver. Symptoms can include jaundice, abdominal pain, and nausea.
Severe Alcohol-Associated Hepatitis: INT-787 Study
We are testing a new medication, INT-787, for individuals with severe alcohol-associated hepatitis. The goal is to see if it can help slow down the progression of this serious liver disease.
3-6 months6-10 visitsEfficacy phase (II)Partially RemoteInvestigational MedicinesOralHepatologyInternal Medicine
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 65 years old?
- Do you have a history of heavy alcohol use (more than 60 grams per day for men or more than 40 grams per day for women) for at least 6 months?
- Are you currently pregnant, planning to become pregnant, or breastfeeding?
- Are you taking any medications that contain corticosteroids, like Prednisone or Hydrocortisone, in the last 30 days?
- Do you have severe heart problems, severe lung disease, or any other serious ongoing health issues?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Int-787
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire D'Angers
Service d’hepato gastro enterologie
Angers, France
Assistance Publique Hopitaux De Paris
Service d’hepatologie
Clichy, France
Centre Hospitalier Universitaire De Lille
Service des maladies de l’appareil digestif et de la nutrition
Loos, France
Sponsor: Intercept Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.